0
Il n'y a pas de produit dans le panier !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Accueil > CCL19

CCL19

Brief Information

Name:C-C motif chemokine 19
Target Synonym:Beta-chemokine exodus-3,CK beta-11,Epstein-Barr virus-induced molecule 1 ligand chemokine,EBI1 ligand chemokine,ELC,Macrophage inflammatory protein 3 beta,MIP-3-beta,Small-inducible cytokine A19,MIP3B,SCYA19
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Phase 1 Clinical

Product ListCompare or Buy

Par statut du produit :
Par catégorie de produit :
Par espèce :
Par étiquette :
Par conjugaison :
Cat . Non Espèces Description du produit Structure Pureté Caractéristique
CC9-H5215 Human Human CCL19 / MIP-3 beta Protein, Tag Free (HPLC verified)
CC9-H5215-structure
CC9-H5215-sds
CC9-H5215-hplc
ACRO Quality

Synonym Name

CCL19,MIP-3 beta,MIP-3-beta,ELC,MIP3B,SCYA19,EBI1 ligand chemokine

Background

C-C motif chemokine 19(CCL19) is as known as CK beta-11, ELC, MIP3B and SCYA19. May play a role not only in inflammatory and immunological responses but also in normal lymphocyte recirculation and homing. May play an important role in trafficking of T-cells in thymus, and T-cell and B-cell migration to secondary lymphoid organs. Binds to chemokine receptor CCR7. Recombinant CCL19 shows potent chemotactic activity for T-cells and B-cells but not for granulocytes and monocytes. Binds to atypical chemokine receptor ACKR4 and mediates the recruitment of beta-arrestin (ARRB1/2) to ACKR4.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Anti-GPC3 chimeric antigen receptor T cell therapy (Hunan Zhaotai Yongren Biotech/Guangdong Zhaotai Invivo Biomedicine) Phase 1 Clinical Hunan Zhaotai Yongren Biotech Co Ltd, Guangdong Zhaotai Invivo Biomedicine Co Ltd Carcinoma, Squamous Cell; Carcinoma, Hepatocellular Details
Anti-GPC3 chimeric antigen receptor T cell therapy (Hunan Zhaotai Yongren Biotech/Guangdong Zhaotai Invivo Biomedicine) Phase 1 Clinical Hunan Zhaotai Yongren Biotech Co Ltd, Guangdong Zhaotai Invivo Biomedicine Co Ltd Carcinoma, Squamous Cell; Carcinoma, Hepatocellular Details

This web search service is supported by Google Inc.

totop

Laisser un message